Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Common Equity (2016 - 2025)

Ironwood Pharmaceuticals' Common Equity history spans 17 years, with the latest figure at -$261.8 million for Q4 2025.

  • For Q4 2025, Common Equity rose 13.11% year-over-year to -$261.8 million; the TTM value through Dec 2025 reached -$261.8 million, up 13.11%, while the annual FY2025 figure was -$261.8 million, 13.11% up from the prior year.
  • Common Equity for Q4 2025 was -$261.8 million at Ironwood Pharmaceuticals, up from -$264.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $706.9 million in Q1 2023 and bottomed at -$1.7 billion in Q4 2023.
  • The 5-year median for Common Equity is -$263.0 million (2025), against an average of $228350.0.
  • The largest annual shift saw Common Equity skyrocketed 9722.85% in 2021 before it crashed 360.37% in 2023.
  • A 5-year view of Common Equity shows it stood at $605.9 million in 2021, then increased by 7.67% to $652.4 million in 2022, then plummeted by 360.37% to -$1.7 billion in 2023, then surged by 82.26% to -$301.3 million in 2024, then grew by 13.11% to -$261.8 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Common Equity are -$261.8 million (Q4 2025), -$264.2 million (Q3 2025), and -$308.2 million (Q2 2025).